StockDrifts LogoStockDrifts

L&K Bio 156100

Company
엘앤케이바이오L&K Bio
Insiders
2
Buys
1
Total Value
₩263M ($183K)
Avg Return
-18.70%
Last Filing
2026-01-14

L&K Bio (156100) has 1 disclosed insider purchases and 1 disclosed disposals on record, filed by 2 distinct insiders. Together those filings cover ₩263M ($183K) in reported transaction value. The earliest filing StockDrifts holds for L&K Bio is dated 2024-03-29; the most recent is 2026-01-14. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is -18.70%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2026-08-03BUYMarket Buy
강국진
Kang Guk-jin
CEO36.6K₩3,385+0.9%₩100M ($70K)
2026-01-14BUYMarket Buy
강국진
Kang Guk-jin
CEO20.0K₩12,710-7.2%₩254M ($177K)
2024-07-19SELLMarket Sell
전혜정
Jeon Hye-jeong
Outside Director-1.0K₩9,060-30.2%₩9M ($6K)
2024-03-29BUY신규선임
전혜정
Jeon Hye-jeong
Outside Director5.1K₩8,500+38.8%₩43M ($30K)

Frequently asked questions

Who has been buying L&K Bio stock?
2 distinct insiders have filed 1 disclosed insider purchases in L&K Bio (156100), most recently on 2026-01-14. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does L&K Bio have?
L&K Bio has 1 buy-side and 1 sell-side disclosures on record, covering ₩263M ($183K) in total reported value, spanning 2024-03-29 to 2026-01-14.
Where does StockDrifts get L&K Bio insider data?
From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for L&K Bio. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.